Skip to main content
Third-party tested
Purity documentation available
Research supply chain
Compliance notice included
KPV
99%+ Purity

KPV Peptide

KPV is a naturally occurring tripeptide composed of lysine, proline, and valine, derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Research demonstrates KPV exhibits potent anti-inflammatory properties by inhibiting NF-κB and MAP kinase signaling pathways while reducing pro-inflammatory cytokine secretion. Studies show the peptide is transported into cells via the PepT1 transporter, where it inactivates inflammatory pathways at nanomolar concentrations. KPV demonstrates antimicrobial activity against major pathogens including Staphylococcus aureus and Candida albicans. Animal studies indicate KPV significantly reduces intestinal inflammation, accelerates wound healing, and improves tissue repair without pigmentation effects. For Research Use Only. Not intended for human or veterinary use.

1
$54.99
We accept

Certificate of Analysis

Third Party TestedISO/IEC 17025 Accredited
ISO 170253rd Party
99.34%
Purity
Passed full QC panel
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
Full QC Panel
Purity (HPLC)99.34%
Net Peptide Content10.54mg
Identity (HPLC)KPV Confirmed
Heavy Metals (ICP-MS)Not Detected
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Identity
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
Full QC Panel
Identity (HPLC)KPV Confirmed
ISO/IEC 17025 Accredited
ISO 170253rd Party
10.54mg
Net Peptide Content
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Fentanyl Screen
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Heavy Metals
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
Full QC Panel
Heavy Metals (ICP-MS)Not Detected
ISO/IEC 17025 Accredited
ISO 170253rd Party
99.34%
Purity
Passed full QC panel
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
Full QC Panel
Purity (HPLC)99.34%
Net Peptide Content10.54mg
Identity (HPLC)KPV Confirmed
Heavy Metals (ICP-MS)Not Detected
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Identity
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
Full QC Panel
Identity (HPLC)KPV Confirmed
ISO/IEC 17025 Accredited
ISO 170253rd Party
10.54mg
Net Peptide Content
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Fentanyl Screen
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Heavy Metals
Lot #KPV-10MG-BA-647
TestedAug 12, 2026
Full QC Panel
Heavy Metals (ICP-MS)Not Detected
ISO/IEC 17025 Accredited

Compound Information

Structured specifications and handling data

Molecular profile

Technical specifications

Type:Synthetic Peptide
CAS Number:67727-97-3
Molecular Weight:384.48 g/mol
Amino Acids:3
Sequence:Ac-Lys-Pro-Val-NH2
Formula:C17H32N6O4
PubChem Database
Storage requirements

Stability and handling

Lyophilized
Cold Storage
Storage TemperatureStore in a cool, dry place away from light; refrigerate at 2–8°C (36–46°F)
ReconstitutionReconstitute with sterile water or bacteriostatic water
StabilityStable when stored properly; avoid repeated freeze-thaw cycles
Chemical structure

Molecular model

3D Interactive

Loading 3D Molecule...

Left click to rotate • Scroll to zoom

KPV research overview

KPV comes from the last three amino acids of alpha-MSH (alpha-melanocyte stimulating hormone), a signaling molecule involved in many biological processes. Researchers identified KPV as the smallest fragment of alpha-MSH that still showed activity in inflammatory cell models, which is what makes it interesting as a research tool. Cells appear to take it up through a transporter called PepT1, which is particularly active in gut lining cells.

The main focus of KPV research has been on NF-kappaB, a protein complex that acts like a master switch for inflammatory genes. When cells are stimulated with inflammatory triggers in lab experiments, KPV has been observed to reduce NF-kappaB activation and lower the release of inflammatory signaling molecules like TNF-alpha, interleukin-1 beta, and interleukin-6. This work has primarily been done in intestinal epithelial cells and colon tissue samples.

Animal research has explored KPV in models of intestinal inflammation, looking at neutrophil activity and inflammatory marker levels. Interestingly, some of its effects appear to work independently of melanocortin receptors, which is unusual for a fragment derived from alpha-MSH. Researchers have also studied its antimicrobial properties against certain bacteria and fungi in laboratory assays. For Research Use Only. Not intended for human or veterinary use.

NF-kappaB Pathway

Laboratory studies have investigated its effects on NF-kappaB nuclear translocation in stimulated cell models.

Cytokine Secretion

Research has examined its association with inflammatory cytokine profiles in cell culture assays.

Peptide Transport

Studies have explored cellular uptake via PepT1 transporter systems in epithelial cell experiments.

Microbial Assays

Microbiological research has investigated its activity against bacterial and fungal strains in laboratory settings.

Research evidence

Published studies and concise summaries for research review.

Research Paper
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
Dalmasso G et al.
Research Paper
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

AI-generated summary of this research paper below.

This pivotal study demonstrated that the tripeptide KPV (Lys-Pro-Val, N- and C-terminally modified) exerts potent anti-inflammatory effects in intestinal epithelial cells and murine models of colitis through PepT1-mediated intracellular uptake. In Caco-2 cells and colonic explants, KPV inhibited NF-κB activation and reduced production of pro-inflammatory cytokines (TNF-α, IL-8) following stimulation with TNF-α or Salmonella. In vivo, oral or intraperitoneal KPV administration in DSS-induced and TNBS-induced colitis models significantly decreased macroscopic/microscopic inflammation scores, weight loss, and mucosal damage, with effects comparable or superior to full α-MSH. The peptide was internalized via PepT1 (a di/tripeptide transporter overexpressed in inflamed epithelium), allowing direct intracellular action independent of melanocortin receptors. These findings established KPV as a promising, orally bioavailable therapeutic for inflammatory bowel disease, highlighting a novel receptor-independent mechanism for targeted anti-inflammatory delivery.
Research overview
Total Papers
49+
Year Range
2000+
Research status
Active
Peer-reviewed studies available
Research FAQ

Frequently asked questions

Concise answers about laboratory context, handling, and documentation for this compound.

Laboratory compliance notice

All compounds sold by Validated Peptides are intended for in-vitro laboratory research only.

These materials are not approved by the FDA for human or animal use and are not intended for diagnostic, therapeutic, or clinical applications.

Purchasers are responsible for compliant handling, storage, and use within an appropriate laboratory environment.

Research Use Only
Not for Human Use
21+ Required